CPT heads into its Q1 2026 results today with a deeply unusual split: the stock has rallied hard this week, yet options positioning has swung to its most defensive reading of the past year.
The options market is sending a loud warning. The put/call ratio spiked to 1.69 on April 28 — more than four standard deviations above its 20-day average of 0.83. That is the second-highest reading in the past year, approaching the 52-week high of 2.28. In plain terms, traders bought puts at a rate roughly double the recent norm in the session immediately before earnings. That kind of late-session hedging surge is a familiar pattern: investors who rode the rally are paying up for downside protection rather than trimming outright.
Short interest provides a contrasting backdrop. At 5.5% of the free float, the position is meaningful but not extreme — and borrow conditions are unambiguously loose. Cost to borrow is just 0.42%, near the cheapest level of the past month and down about 12% over 30 days. With availability well above tight thresholds, there is no squeeze dynamic in the lending market: short sellers face no material friction adding or removing positions. Short interest did rise around 16% over the past month, but the daily reading eased back modestly through the final week of April — suggesting shorts trimmed rather than pressed into the rally. The ORTEX short score is a moderate 44.6, well below the 70+ levels typically associated with crowded positioning.
The Street is neutral, but the targets have been drifting lower. Wells Fargo, the most recent mover, cut its target to $106 just last week — almost exactly where the stock closed at $105.93. That is a notably precise marker: CPT is trading right at the level one large REIT specialist considers fair value. Morgan Stanley and Barclays both trimmed targets in March, while earlier in the quarter Mizuho and Truist moved theirs higher. The net result is a consensus mean target around $114, implying roughly 8% upside — not a demanding bar, but not a ringing buy either. The EV/EBITDA multiple has expanded about 3% over the past 30 days to 17.5x, tracking the price recovery. One standout factor: CPT ranks in the 97th percentile on EPS surprise history, meaning the company has a strong track record of beating estimates. That figure supports the bull case for a clean beat today. Bulls point to an expected 2.6% same-store revenue growth in 2026 and a projected 4.6% average annual FFO per share growth through 2030. Bears counter with the lowered 2026 FFO estimate (now $7.05 vs. the prior $7.19) and rising pressure from new supply in key markets including Houston and Washington D.C.
The institutional base is anchored. Vanguard holds 16.1% and BlackRock another 10.2%, both essentially unchanged. The more notable move is Goldman Sachs Asset Management adding roughly 938,000 shares in the most recent reporting period — a position built from near zero to just under 2% of shares. On the insider side, the recent picture is one of controlled selling: CEO Richard Campo sold approximately $4.8 million across two tranches in early January near $110, while CFO Alex Jessett and COO Laurie Baker made smaller routine sales around the same time. None of these transactions carry high significance scores, and there has been no insider activity since February, leaving the net 90-day picture dominated by that CEO selling cluster.
The multifamily REIT sector has moved sharply with CPT this week. Close peers MAA, UDR, and EQR are all up between 3.5% and 5.3% on the week, with AVB leading the peer group at nearly 6.6%. CPT's 3.4% weekly gain is the softest of the group — a relative lag that may partly reflect the specific supply concerns in its Sun Belt-heavy portfolio.
The key question heading into today's print is whether a company with a near-top-decile EPS surprise track record can beat a well-managed FFO bar — while the options market makes clear that holders are not taking that outcome for granted.
See the live data behind this article on ORTEX.
Open CPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
